Trial Profile
A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-steroidal Aromatase Inhibitors.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 26 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 26 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2011 Planned End Date changed from 1 Apr 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.